Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
Ist Teil von
British journal of cancer, 2009-02, Vol.100 (3), p.487-493
Ort / Verlag
London: Nature Publishing Group UK
Erscheinungsjahr
2009
Quelle
MEDLINE
Beschreibungen/Notizen
The clinical significance of
ERBB2
amplification/overexpression in gastric cancer remains unclear. In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence
in situ
hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival. ERBB2 overexpression (2+ and 3+) and amplification (ratio
ERBB2
/CEP17⩾2) were found in 43 (9.3%) and 38 (8.2%) gastric carcinomas, respectively. Perfect IHC/FISH correlation was found for the 19 cases scored as 0 (all negative by FISH), and also for the 25 cases scored as 3+ (all positive by FISH). One out of six carcinomas scored as 1+ and 12 out of 18 carcinomas scored as 2+ were positive by FISH.
ERBB2
amplification was associated with gastric carcinomas of intestinal type (
P
=0.007) and with an expansive growth pattern (
P
=0.021).
ERBB2
amplification was detected in both histological components of two mixed carcinomas, indicating a common clonal origin. A statistically significant association was found between
ERBB2
amplification and worse survival in patients with expansive gastric carcinomas (
P
=0.011). We conclude that ERBB2 status may have clinical significance in subsets of gastric cancer patients, and that further studies are warranted to evaluate whether patients whose gastric carcinomas present
ERBB2
amplification/overexpression may benefit from therapy targeting this surface receptor.